The DNA Resource Core was founded in 1999 and has been continuously funded by the CCSG as a DF/HCC Shared Resources since 2000. The facility is currently led by J. Wade Harper and is jointly managed (Cancer Center and Institution). The Core provides investigators access to specialized resources such as informatics support, rapid and user-friendly high-throughput DNA sequencing services and cDNA/RNAi clone repository and distribution services. The success of the DNA Resource Core is evidenced by its usage, sequencing about 200,000 samples per year. In 2004, the PlasmID DNA repository and associated in-house plasmid database was added. This repository's current collection includes more than 241,000 plasmid DNA clones useful for cloning, mutagenesis and expression relevant to more than 25 different species, with the emphasis on human cancer-related gene collections. In addition, based on the expressed need of DF/HCC members, the DNA Resource Core has now integrated shRNA libraries into the PlasmID DNA repository. Director: J. Wade Harper, PhD(HMS) Category: 1.2 (Molecular Biology) Management: Joint (Cancer Center and Institution).
The DNA Resource Core was created to address the sequencing needs of both small-and large-scale DNA sequencing users in DF/HCC. The Core's mission is to provide quality and priority access to specialized resources and services. These services constitute an integral component of the vast majority of basic and translational sciences being done under the umbrella of DF/HCC.
|Lin, Ruei-Zeng; Lee, Chin Nien; Moreno-Luna, Rafael et al. (2017) Host non-inflammatory neutrophils mediate the engraftment of bioengineered vascular networks. Nat Biomed Eng 1:|
|Wang, Meng; Han, Jing; Marcar, Lynnette et al. (2017) Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res 77:2018-2028|
|Ignatius, Myron S; Hayes, Madeline N; Lobbardi, Riadh et al. (2017) The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Rep 19:2304-2318|
|Nugent, Alicia A; Park, Jong G; Wei, Yan et al. (2017) Mutant ?2-chimaerin signals via bidirectional ephrin pathways in Duane retraction syndrome. J Clin Invest 127:1664-1682|
|Breitkopf, Susanne B; Taveira, Mateus De Oliveira; Yuan, Min et al. (2017) Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland. Sci Rep 7:14503|
|Bowden, John A; Heckert, Alan; Ulmer, Candice Z et al. (2017) Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma. J Lipid Res 58:2275-2288|
|Lindsley, R Coleman; Saber, Wael; Mar, Brenton G et al. (2017) Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 376:536-547|
|Mita, Monica M; Mita, Alain C; Moseley, Jennifer L et al. (2017) Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br J Cancer 117:1258-1268|
|Hu, Yuebi; Alden, Ryan S; Odegaard, Justin I et al. (2017) Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res 23:7351-7359|
|Lam, Hilaire C; Liu, Heng-Jia; Baglini, Christian V et al. (2017) Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget 8:64714-64727|
Showing the most recent 10 out of 371 publications